New opportunities of the therapy of medicinal ophthalmic allergies
https://doi.org/10.21516/2072-0076-2017-10-3-108-112
Abstract
Drug allergy is one of the most common issues not only in ophthalmology, but in the general medicine. Drug-induced conjunctivitis is an inflammatory reaction of the conjunctiva, allergic or toxic, caused by the use of medicines. The frequency and severity of drug-induced conjunctivitis continuously increase as the arsenal of biologically active drugs increases. The purpose of the paper is to compare the efficacy of eye drops Opatanol (0.1 % olopatadine) and Vizallergol (0.2 % olopatadine) in the therapy of drug conjunctivitis. Materials and methods. Clinical observation involved 42 patients (26 women and 16 men) with drug conjunctivitis aged 28 to 56, which were divided into two groups. Group 1 (22 patients) received 2 drops of Opatanol twice a day, whill group 2 (20 patients) received 2 drops of Vizallergol once a day. The clinical observation included careful collection of history data, visometry andbiomicroscopy with the assessment of the condition of the eyelids and conjunctiva, taking into account the follicular reaction on a 3-point scale. Results. In the process of treatment, subjective sensations (itching, burning, discomfort) were found to gradually reduce in both clinical groups. The average duration of treatment in group 1 was 11 ± 0.1 days, in group 2 - 9 ± 0.3 days. Conclusion. The therapeutic effect of Vizallergol was somewhat higher than that of Opatanol, which is explained by a higher concentration of the main active substance, olopatadine. For citations: Jani E.V., Pozdnyakova V.V., Seliverstova K.E. New opportunities of the therapy of medicinalophthalmic allergies. Russian ophthalmological journal. 2017; 10 (3): 108-112. doi: 10.21516/2072-0076-2017-10-3-108-112 (in Russian).
About the Authors
E. V. Jani
Moscow Helmholtz Research Institute of Eye Diseases,, Moscow, Russia
Russian Federation
Russian Federation
V. V. Pozdnyakova
Moscow Helmholtz Research Institute of Eye Diseases,, Moscow, Russia
Russian Federation
Russian Federation
K. E. Seliverstova
Moscow Helmholtz Research Institute of Eye Diseases,, Moscow, Russia
Russian Federation
Russian Federation
References
1. Friedlender M.H. Allergic conjunctivitis. In: Frannfeder F.T., Roy F.H., Randall W.B., eds. Current ocular therapy. Saunders; 2000.
2. Reinhard T., Larkin F., eds. Cornea and external eye disease. Berlin Heidelberg: Springer; 2006.
3. Johansson S.G.O., Haahtela T. Всемирная организация по аллергии: руководство по профилактике аллергии и аллергической астмы. Аллергия и иммунология. 2005; 1: 81-91.
4. Billory L. Allergic diseases of the eye. Med. Clin. N. Am. 2006; 90: 129-48.
5. Abelson M.B. Allergic disease of the eye. Sauders Co (Philadelphia); 2001.
6. Яни Е.В., Селиверстова К.Е. Токсико-аллергический конъюнктивит у пациентов с первичной глаукомой на фоне медикаментозного гипотензивного лечения. Фарматека. 2016; 20: 12-4.
7. Майчук Ю.Ф. Опатанол (олопатадин 0,1%) - глазные капли двойного противоаллергического механизма действия. Клиническая офтальмология. 2007; 8(2): 1-4.
8. Leonardi A. Emerging drugs for ocular allergy. Emerg. Drugs. 2005; 10(3): 505-20.
9. Майчук Ю.Ф., Поздняков В.И., Позднякова В.В., Якушина Л.Н. Противоаллергические глазные капли "Полинадим": разработка, экспериментальные и клинические исследования. Вестник офтальмологии. 2006; 122(5): 35-8.
10. Опатанол. Инструкция по применению. Москва: Алкон-Куврер Н.В С.А; 2005. Opatanol. Instructions for use. Alcon-Couvreur N. V. Moscow; 2005. (In Russian).
11. Майчук Ю.Ф., Позднякова В.В, Якушина Л.Н. Глазные капли Опатанол (олопатадин 0,1%) в терапии аллергических заболеваний глаз. Клиническая офтальмология. 2007; 8(3): 115-7.
Review
For citations:
Jani E.V., Pozdnyakova V.V., Seliverstova K.E. New opportunities of the therapy of medicinal ophthalmic allergies. Russian Ophthalmological Journal. 2017;10(3):108-112. (In Russ.) https://doi.org/10.21516/2072-0076-2017-10-3-108-112
Views:
2940
Email this article 